Hacia una nueva era en el diagnóstico y tratamiento de la enfermedad de Alzheimer

Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, et al. Dementia prevention, intervention, and care. Lancet. 2017;390(10113):2673-734. DOI: https://doi.org/10.1016/S0140-6736(17)31363-6

Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413-46. DOI: https://doi.org/10.1016/S0140-6736(20)30367-6

Patterson C. World Alzheimer report 2018. London: Alzheimer’s Disease International. 2018.

WHO. Dementia [Internet]. 2022 [cited 2023 Mar 21]. Available from: https://www.who.int/news-room/fact-sheets/detail/dementia.

Gale SA, Acar D, Daffner KR. Dementia. Am J Med. 2018;131(10):1161-9. DOI: https://doi.org/10.1016/j.amjmed.2018.01.022

Polanco JC, Li C, Bodea LG, Martinez-Marmol R, Meunier FA, Gotz J. Amyloid-beta and tau complexity – towards improved biomarkers and targeted therapies. Nat Rev Neurol. 2018;14(1):22-39. DOI: https://doi.org/10.1038/nrneurol.2017.162

Knopman DS, Amieva H, Petersen RC, Chetelat G, Holtzman DM, Hyman BT, et al. Alzheimer disease. Nat Rev Dis Primers. 2021;7(1):33. DOI: https://doi.org/10.1038/s41572-021-00269-y

Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J, eds. Harrison’s principles of internal medicine. 20th ed. New York: McGraw Hill; 2018.

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34(7):939-44. DOI: https://doi.org/10.1212/WNL.34.7.939

Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27(6):954-63. DOI: https://doi.org/10.1038/s41591-021-01382-x

Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger- Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6(8):734-46. DOI: https://doi.org/10.1016/S1474-4422(07)70178-3

Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614-29. DOI: https://doi.org/10.1016/S1474-4422(14)70090-0

Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, et al. Preclinical Alzheimer’s disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016;12(3):292-323. DOI: https://doi.org/10.1016/j.jalz.2016.02.002

Dubois B, Villain N, Frisoni GB, Rabinovici GD, Sabbagh M, Cappa S, et al. Clinical diagnosis of Alzheimer’s disease: recommendations of the International Working Group. Lancet Neurol. 2021;20(6):484-96. DOI: https://doi.org/10.1016/S1474-4422(21)00066-1

Jack CR, Jr., Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, et al. Introduction to the recommendations from the National Institute on Aging- Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):257-62. DOI: https://doi.org/10.1016/j.jalz.2011.03.004

Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):270-9. DOI: https://doi.org/10.1016/j.jalz.2011.03.008

McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr., Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263-9. DOI: https://doi.org/10.1016/j.jalz.2011.03.005

Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):280-92. DOI: https://doi.org/10.1016/j.jalz.2011.03.003

Jack CR, Jr., Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535-62. DOI: https://doi.org/10.1016/j.jalz.2018.02.018

Schilling LP, Balthazar MLF, Radanovic M, Forlenza OV, Silagi ML, Smid J, et al. Diagnosis of Alzheimer’s disease: recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology. Dement Neuropsychol. 2022;16(3 Suppl 1):25-39. DOI: https://doi.org/10.1590/1980-5764-dn-2022-s102pt

Karikari TK, Ashton NJ, Brinkmalm G, Brum WS, Benedet AL, Montoliu-Gaya L, et al. Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. Nat Rev Neurol. 2022;18(7):400-18. DOI: https://doi.org/10.1038/s41582-022-00665-2

Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Dore V, et al. High performance plasma amyloid- beta biomarkers for Alzheimer’s disease. Nature. 2018;554(7691):249-54. DOI: https://doi.org/10.1038/nature25456

Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, et al. High-precision plasma beta- amyloid 42/40 predicts current and future brain amyloidosis. Neurology. 2019;93(17):e1647-e59. DOI: https://doi.org/10.1212/WNL.0000000000008081

De Meyer S, Schaeverbeke JM, Verberk IMW, Gille B, De Schaepdryver M, Luckett ES, et al. Comparison of ELISA- and SIMOA-based quantification of plasma Aβ ratios for early detection of cerebral amyloidosis. Alzheimers Res Ther. 2020;12(1):162. DOI: https://doi.org/10.1186/s13195-020-00728-w

Janelidze S, Teunissen CE, Zetterberg H, Allué JA, Sarasa L, Eichenlaub U, et al. Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease. JAMA Neurol. 2021;78(11):1375-82. DOI: https://doi.org/10.1001/jamaneurol.2021.3180

Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19(5):422-33. DOI: https://doi.org/10.1016/S1474-4422(20)30071-5

Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, et al. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. Jama. 2020;324(8):772-81. DOI: https://doi.org/10.1001/jama.2020.12134

Ashton NJ, Pascoal TA, Karikari TK, Benedet AL, Lantero- Rodriguez J, Brinkmalm G, et al. Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology. Acta Neuropathol. 2021;141(5):709-24. DOI: https://doi.org/10.1007/s00401-021-02275-6

Ashton NJ, Janelidze S, Mattsson-Carlgren N, Binette AP, Strandberg O, Brum WS, et al. Differential roles of Abeta42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring. Nat Med. 2022. DOI: https://doi.org/10.1038/s41591-022-02074-w

Mattsson N, Andreasson U, Zetterberg H, Blennow K, Alzheimer’s Disease Neuroimaging I. Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurol. 2017;74(5):557-66. DOI: https://doi.org/10.1001/jamaneurol.2016.6117

Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurol. 2019;76(7):791-9. DOI: https://doi.org/10.1001/jamaneurol.2019.0765

Benedet AL, Leuzy A, Pascoal TA, Ashton NJ, Mathotaarachchi S, Savard M, et al. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer’s disease. Brain. 2020;143(12):3793-804. DOI: https://doi.org/10.1093/brain/awaa342

Pereira JB, Janelidze S, Smith R, Mattsson-Carlgren N, Palmqvist S, Teunissen CE, et al. Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease. Brain. 2021;144(11):3505-16. DOI: https://doi.org/10.1093/brain/awab223

Benedet AL, Milà-Alomà M, Vrillon A, Ashton NJ, Pascoal TA, Lussier F, et al. Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum. JAMA Neurol. 2021;78(12):1471-83. DOI: https://doi.org/10.1001/jamaneurol.2021.3671

Ferrari-Souza JP, Ferreira PCL, Bellaver B, Tissot C, Wang Y-T, Leffa DT, et al. Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer’s disease. Molecular Psychiatry. 2022. DOI: https://doi.org/10.1038/s41380-022-01716-2

Angioni D, Delrieu J, Hansson O, Fillit H, Aisen P, Cummings J, et al. Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force. J Prev Alzheimers Dis. 2022;9(4):569-79. DOI: https://doi.org/10.14283/jpad.2022.85

Ferreira P, Ferrari-Souza JP, Tissot C, Bellaver B, Leffa D, Lussier F, et al. Potential Utility of Plasma P-Tau and Neurofilament Light Chain as Surrogate Biomarkers for Preventive Clinical Trials. Neurology. 2023. DOI: https://doi.org/10.1212/WNL.0000000000207115

Jack CR, Jr. Advances in Alzheimer’s disease research over the past two decades. Lancet Neurol. 2022;21(10):866-9. DOI: https://doi.org/10.1016/S1474-4422(22)00298-8

McAleese KE, Walker L, Erskine D, Thomas AJ, McKeith IG, Attems J. TDP-43 pathology in Alzheimer’s disease, dementia with Lewy bodies and ageing. Brain Pathol. 2017;27(4):472-9. DOI: https://doi.org/10.1111/bpa.12424

Robinson JL, Lee EB, Xie SX, Rennert L, Suh E, Bredenberg C, et al. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain. 2018;141(7):2181-93. DOI: https://doi.org/10.1093/brain/awy146

Wennberg AM, Whitwell JL, Tosakulwong N, Weigand SD, Murray ME, Machulda MM, et al. The influence of tau, amyloid, alpha-synuclein, TDP-43, and vascular pathology in clinically normal elderly individuals. Neurobiol Aging. 2019;77:26-36. DOI: https://doi.org/10.1016/j.neurobiolaging.2019.01.008

Kawas CH, Kim RC, Sonnen JA, Bullain SS, Trieu T, Corrada MM. Multiple pathologies are common and related to dementia in the oldest-old: The 90+ Study. Neurology. 2015;85(6):535-42. DOI: https://doi.org/10.1212/WNL.0000000000001831

James BD, Wilson RS, Boyle PA, Trojanowski JQ, Bennett DA, Schneider JA. TDP-43 stage, mixed pathologies, and clinical Alzheimer’s-type dementia. Brain. 2016;139(11):2983-93. DOI: https://doi.org/10.1093/brain/aww224

Power MC, Mormino E, Soldan A, James BD, Yu L, Armstrong NM, et al. Combined neuropathological pathways account for age related risk of dementia. Ann Neurol. 2018;84(1):10-22. DOI: https://doi.org/10.1002/ana.25246

Karanth S, Nelson PT, Katsumata Y, Kryscio RJ, Schmitt FA, Fardo DW, et al. Prevalence and Clinical Phenotype of Quadruple Misfolded Proteins in Older Adults. JAMA Neurol. 2020;77(10):1299-307. DOI: https://doi.org/10.1001/jamaneurol.2020.1741

Cummings J. New approaches to symptomatic treatments for Alzheimer’s disease. Mol Neurodegener. 2021;16(1):2. DOI: https://doi.org/10.1186/s13024-021-00424-9

Briggs R, Kennelly SP, O’Neill D. Drug treatments in Alzheimer’s disease. Clin Med (Lond). 2016;16(3):247-53. DOI: https://doi.org/10.7861/clinmedicine.16-3-247

Sharma K. Cholinesterase inhibitors as Alzheimer’s therapeutics (Review). Mol Med Rep. 2019;20(2):1479-87. DOI: https://doi.org/10.3892/mmr.2019.10374

Steinbrook R. The Accelerated Approval of Aducanumab for Treatment of Patients With Alzheimer Disease. JAMA Internal Medicine. 2021;181(10):1281. DOI: https://doi.org/10.1001/jamainternmed.2021.4622

Larkin HD. Lecanemab Gains FDA Approval for Early Alzheimer Disease. JAMA. 2023;329(5):363. DOI: https://doi.org/10.1001/jama.2022.24490

Brockmann R, Nixon J, Love BL, Yunusa I. Impacts of FDA approval and Medicare restriction on antiamyloid therapies for Alzheimer’s disease: patient outcomes, healthcare costs, and drug development. Lancet Reg Health Am. 2023;20:100467. DOI: https://doi.org/10.1016/j.lana.2023.100467

Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, et al. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease. J Prev Alzheimers Dis. 2022;9(2):197-210. DOI: https://doi.org/10.14283/jpad.2022.30

van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in Early Alzheimer’s Disease. N Engl J Med. 2023;388(1):9-21. DOI: https://doi.org/10.1056/NEJMoa2212948

Lancet. Lecanemab for Alzheimer’s disease: tempering hype and hope. Lancet. 2022;400(10367):1899. DOI: https://doi.org/10.1016/S0140-6736(22)02480-1

Cummings J, Lee G, Nahed P, Kambar M, Zhong K, Fonseca J, et al. Alzheimer’s disease drug development pipeline: 2022. Alzheimers Dement (N Y). 2022;8(1):e12295. DOI: https://doi.org/10.1002/trc2.12295

Stephenson D, Perry D, Bens C, Bain LJ, Berry D, Krams M, et al. Charting a path toward combination therapy for Alzheimer’s disease. Expert Rev Neurother. 2015;15(1):107-13. DOI: https://doi.org/10.1586/14737175.2015.995168

Perry D, Sperling R, Katz R, Berry D, Dilts D, Hanna D, et al. Building a roadmap for developing combination therapies for Alzheimer’s disease. Expert Rev Neurother. 2015;15(3):327-33. DOI: https://doi.org/10.1586/14737175.2015.996551

Hendrix JA, Bateman RJ, Brashear HR, Duggan C, Carrillo MC, Bain LJ, et al. Challenges, solutions, and recommendations for Alzheimer’s disease combination therapy. Alzheimers Dement. 2016;12(5):623-30. DOI: https://doi.org/10.1016/j.jalz.2016.02.007

Gauthier S, Alam J, Fillit H, Iwatsubo T, Liu-Seifert H, Sabbagh M, et al. Combination Therapy for Alzheimer’s Disease: Perspectives of the EU/US CTAD Task Force. J Prev Alzheimers Dis. 2019;6(3):164-8. DOI: https://doi.org/10.14283/jpad.2019.12